A New Hope for ALS: Drug Shows Rare Ability to Slow—and Even Improve—Symptoms

A groundbreaking new drug called tofersen has become the first treatment to not only slow the progression of amyotrophic lateral sclerosis (ALS) but actually stabilize and improve symptoms in some patients with a rare genetic form of the disease. The Food and Drug Administration (FDA) approved tofersen under its accelerated approval pathway for patients whose ALS is caused by mutations in the SOD1 gene, affecting about 2% of the 20,000 Americans living with this devastating condition.

How Does This New ALS Treatment Actually Work?

Tofersen, also known by the brand name Qalsody, represents a completely new approach to treating ALS. Unlike previous treatments that only managed symptoms, this drug targets the root cause of SOD1 ALS by using modified DNA molecules called antisense oligonucleotides. These molecules interfere with the genetic instructions that produce the toxic SOD1 protein responsible for killing nerve cells in this form of ALS.

The drug is delivered directly into the cerebrospinal fluid that bathes the brain and spinal cord, allowing it to reach the affected neurons. In the phase 3 clinical trial known as the VALOR trial, tofersen reduced levels of both SOD1 protein and neurofilament light protein, a key marker of neurological damage, within the first six months of treatment.

What Results Did Patients Actually Experience?

The clinical trial results showed something unprecedented in ALS treatment. While the drug's benefits took time to become apparent, researchers observed remarkable changes after about six months of treatment. The study involved 24 participants at Washington University alone, with additional patients at other sites.

Key improvements patients experienced included:

• Stabilized muscle strength: Patients stopped experiencing the typical relentless decline in muscle function that characterizes ALS
• Improved motor control: Some participants showed objective improvements in their ability to control muscle movements
• Reduced neurodegeneration: Molecular markers indicated the drug was actually slowing the death of nerve cells

"As a physician caring for many ALS patients, the degree of benefit exhibited by some patients treated with tofersen has been impressive. ALS patients normally experience a relentless, progressive decline. These results have transformed my perspective on ALS as a treatable disorder," said Robert Bucelli, MD, PhD, a professor of neurology and co-director of Washington University's ALS Center.

Why Is This Breakthrough So Significant for ALS Research?

This approval represents a paradigm shift in how researchers approach ALS treatment. For decades, ALS has been considered essentially untreatable, with most patients experiencing rapid decline and death within five years of diagnosis. The success of tofersen proves that the disease can be modified when researchers understand its underlying mechanisms.

Timothy Miller, MD, PhD, the principal investigator who led the tofersen clinical trials, spent two decades developing this approach. He focused on SOD1 ALS specifically because, unlike the majority of ALS cases that occur seemingly at random, this genetic form has a clear, identifiable cause that could be targeted therapeutically.

"My whole career has been built on the assumption that ALS is a treatable disorder. It's all about finding the right therapy. Tofersen appears to be the right therapy for SOD1 ALS. Now we have to find the right therapy for other forms of ALS," Miller explained.

While tofersen only helps the small percentage of ALS patients with SOD1 mutations, its success provides a roadmap for developing treatments for other forms of the disease. The antisense oligonucleotide technology used in tofersen could potentially be adapted to target other disease-causing proteins in different types of ALS, offering hope for the broader ALS community.